Using an innovative Q-Mol™ computational lead discovery technology in combination with the de novo design approaches, our team is focusing on the discovery and development of ligands for allosteric sites and protein-protein interactions for mechanistically novel and “difficult” validated targets.

Our breakthrough computational approaches allow accelerated lead discovery for unconventional drug targets without the need for time consuming and costly high throughput screening of compound libraries. The entire commercial chemical space of ~8 mln compounds can be assessed very rapidly and at the fraction of the cost of conventional HTS.

Ability to deliberately target allosteric and protein-protein interactions distinguishes us from our competitors. As majority of pharmaceutical efforts are concentrated on ligands targeting active sites, this presents an "untapped" market opportunity for mechanistically novel blockbuster drugs.